{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-22-000022","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.839980+00:00","generated_at":"2026-06-23T00:35:41.247116+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Gilead Q3 revenue $7.0B, EPS $1.42; raises full-year guidance","bullets":["Total revenue $7.0B (-5% YoY); core product sales ex-Veklury up 11% to $6.1B.","GAAP diluted EPS $1.42 (vs $2.05); Non-GAAP EPS $1.90 (vs $2.65).","Biktarvy sales +22% to $2.8B; oncology sales +79% to $578M; Veklury -52% to $925M.","Raises 2022 guidance: product sales $25.9-$26.2B, Non-GAAP EPS $6.95-$7.15.","Acquired IPR&D $448M, including $389M for MiroBio; operating CF $2.9B in Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-22-000022","json":"https://secwatch.observer/filing/0000882095-22-000022.json","markdown":"https://secwatch.observer/filing/0000882095-22-000022.md","text":"https://secwatch.observer/filing/0000882095-22-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000022/0000882095-22-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000022/gild-20221027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:35:41.247116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}